Report on healthcare associatedStaphylococcus aureus bacteraemia workshop

Thursday 14 August 2014

Background

Staphylococcus aureus is harmlessly carried by most people. It often causesminor skin infections, which sometimes enterthe bloodstream causing serious infection (also known as bacteraemia) with mortality rates of 15 to 35%. Most healthcare associated Staphylococcus aureusbacteraemia (SAB) is caused by a medical procedure (such as insertion of an intravenous line) or surgery and is potentially preventable. While SAB can be treated with antibiotics, treatment almost always starts in hospital. Sometimes last-line antibiotics are needed which is associated with increased mortality. And patients infected with resistant strains are more likely to have complications causing a longer and more costly hospital stay. An overseas study estimated the extra cost to be $25,000 to $50,000 per patient.

In 2009 the Australian Commission on Safety and Quality in Health Care (the Commission) developed a case definition of healthcare associated SAB that was and endorsed by all Australian states and territories. This allows national reporting and bench marking.In 2000, the Australian Group on Antimicrobial Resistance started a SAB surveillance program and the 2012 survey showed thatMRSA SAB had reduced from 5.9% in 2010 to 5.1% in 2012. Similarly, between 2010/11 and 2012/13, the Australian Institute of Health and Welfare reported the national rates of SAB reduced from 1.1 cases per 10,000 patient days to 0.9 cases per 10,000 patient days, (p<0.001).

To support a coordinated and efficient national approach to SAB reporting and surveillance, the Healthcare Associated Infection Special Interest Group of the Australian Society for Infectious Diseases invited the Commission to co-host a workshop with the Australasian College of Infection Prevention and Control.The workshop was for infectious diseases physicians, clinical microbiologists, infection prevention and control professionals, jurisdictional representatives and other interested clinicians. The areas covered in the workshop included surveillance, successful initiatives, SAB event evaluation and experiences and a report is being prepared

Report on healthcare associated Staphylococcus aureaus bacteraemia workshop

Healthcare associated Staphlycoccus aureus bloodstream infection workshop agenda

14 August 2014

Co-hosted HICSIG of ASID / ACIPC

Chairs Associate Professor Eugene Athan Convenor HICSIG of ASID

Dr Marilyn Cruickshank ACSQHC

9:30am Registration tea, coffee and muffins

10:00amIntroduction and PurposeAssociate Professor Eugene Athan

Surveillance

10:20amHistory of SAB surveillance in AustraliaDr Marilyn Cruickshank, ACSQHC

10:40amStrengths and weaknesses Professor Mary-Louise McLaws, UNSW

Associate Professor Leon Worth, Peter MacCallum Cancer centre/VICNISS

Successful Initiatives

11:40amZero CLABSIs in Adult ICUBarwon Health Geelong, Associate Professor Neil Orford

12:00pmPeripheral IV cannulationAustin Health, Professor Lindsay Grayson

12:20pmPreventing CLABSIs in NICUAdelaide Women & Children’s Hospital, Ms Jan Whitelaw

Questions

12:30pm Lunch Break

SAB event validation and experiences

1:30pmCanberra Professor Peter Collignon

1:50pmNewcastleAssociate Professor John Ferguson

2:10pmBrisbane Dr Naomi Runnegar

2:10pm Panel discussion/debate and the way forward60 min

3:10pmSummation

3:30 pmClose

Report on healthcare associated Staphylococcus aureaus bacteraemia workshopPage 1 of 2